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Recent studies have demonstrated that lifestyle and medication
interventions can delay or prevent progression from impaired
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To develop and validate an empirical equation to screen for dysglycaemia





A predictive equation was developed using multiple logistic regression
analysis and data collected from 1032 Egyptian subjects with no history of diabetes.
The equation incorporated age, sex, body mass index (BMI), post-prandial time
(self-reported number of hours since last food or drink other than water), systolic
blood pressure, high-density lipoprotein (HDL) cholesterol and random capillary
plasma glucose as independent covariates for prediction of dysglycaemia based




 6.1 mmol/ l and/or plasma glucose 2 h after




 7.8 mmol/ l. The equation was validated us-
ing a cross-validation procedure. Its performance was also compared with static

















8.3390 + 0.0214 (age in years) +




) + 0.0934 (post-prandial time in hours) +




 0.0110 (HDL in mmol/ l) + 0.0243
(random capillary plasma glucose in mmol/ l). The cut-point for the prediction




 0.38. The equation’s sensitivity
was 55%, specificity 90% and positive predictive value (PPV) 65%. When applied




This multivariate logistic equation improves on currently recom-
mended methods of screening for dysglycaemia and can be easily implemented
in a clinical setting using readily available clinical and non-fasting laboratory
data and an inexpensive hand-held programmable calculator.




capillary glucose, impaired fasting glucose, impaired glucose




EPV, events per variable; FPG, fasting plasma glucose; HDL,
high-density lipoprotein; IFG, impaired fasting glucose; IGT, impaired glucose
tolerance; LDL, low-density lipoprotein; OAPR, odds of being affected given a
positive result; PPV, positive predictive value
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lack of randomized controlled clinical trials, there is also growing
evidence that earlier detection of Type 2 diabetes, improved
glycaemic control and intensified risk factor management may
result in clinically important improvements in diabetes-related
morbidity and mortality [6,7]. Unfortunately, there is no
consensus as to the most effective, efficient and cost-effective
means to screen for dysglycaemia defined as impaired fasting
glucose (IFG), IGT and previously undiagnosed diabetes.
Ideally, any screening test should be safe, acceptable, simple,
cheap, sensitive, specific and reliable [6]. Although the 75-g oral
glucose tolerance test represents the gold standard for diagnos-
ing dysglycaemia, it is hardly acceptable, simple or cheap for
routine use. In this report, we develop, validate and evaluate a
simple approach to screening for dysglycaemia that employs
data from a brief history, physical examination, routine non-




To assess the likelihood of dysglycaemia, we developed a pre-
dictive equation using data from 1032 Egyptian subjects with-
out a history of diabetes who participated in the Diabetes in
Egypt Project between July 1992 and October 1993 [8]. The
project was approved by the Egyptian Ministry of Health, the
US Agency for International Development and the University of
Michigan Institutional Review Board. All subjects provided
informed consent. On the first visit, all subjects were assessed
for age, sex, post-prandial time (self-reported number of hours
since last food or drink other than water), family history of
diabetes and random capillary whole blood glucose. On a
separate day, height, weight, waist circumference, systolic and
diastolic blood pressure, fasting total cholesterol, triglycerides,
high-density lipoprotein (HDL), fasting plasma glucose (FPG)
and plasma glucose 2 h after a 75-g oral glucose load (2-h PG)
were measured. Random capillary whole blood glucose was
measured using a portable reflectance meter (One Touch II,
LifeScan Inc., Milpitas, CA, USA). FPG, 2-h PG and lipids were
measured using a Kodak Ektachem DT60II analyser (Eastman
Kodak Co., Rochester, NY, USA).
Bivariate logistic regression analysis and stepwise selection
procedures were used to select the best possible multivariate
model from a panel of risk factors that are available in routine
clinical practice. The panel included age, sex, BMI, waist circum-
ference, hip circumference, systolic blood pressure, diastolic
blood pressure, total cholesterol, HDL, low-density lipoprotein
(LDL), triglycerides, post-prandial time, random capillary
plasma glucose and family history of diabetes. Multiple logistic
regression analysis was then used to develop an equation to









 7.8 mmol/ l. Risk factors in the final model included age
(years), sex (female), body mass index (BMI) calculated as weight





time (0–8+ h), systolic blood pressure (mmHg), HDL (mmol/ l)
and random capillary plasma glucose (mmol/ l). Capillary plasma
glucose values were calculated by multiplying capillary whole
blood glucose values by 1.14. Age, BMI, systolic blood pressure,
HDL and capillary plasma glucose were modelled as continuous
variables; post-prandial time was modelled as a continuous
variable between 0 and 8 h (after which random capillary glucose
did not vary as a function of post-prandial time); and sex was
modelled as a categorical variable (0 = male and 1 = female).
The final mathematical equation provides an estimate of a
subject’s likelihood of dysglycaemia expressed as a probability
between 0.0 and 1.0.
The methodology and model-building process are described
in detail elsewhere [9]. Briefly, descriptive statistics were obtained
for all variables. We assessed multicollinearity and the linearity
assumption for logistic regression equation. Accuracy, reliability
and precision of regression coefficients were assessed by calculat-
ing the number of events per variable (EPV), the ratio of the
number of outcome events to the number of predictor variables
[10,11]. In general, the validity of a logistic regression equation
becomes problematic when the EPV is < 10. The possible inter-












2 Log Likelihood Ratio test was used to test the overall
significance of the predictive equation. The significance of the







odds ratios and 95% confidence intervals. The fit of the model








To select the optimal cut-point to define a positive test, a re-
ceiver operating characteristic (ROC) curve was constructed by
plotting sensitivity against the false positive rate (1-specificity)
over a range of cut-point values. We purposefully selected a cut-
point on the ROC curve to ensure a specificity of approximately
90%. To assess the ability of the equation to predict outcome
for study subjects, sensitivity, specificity, positive predictive
value (PPV), and the odds of being affected given a positive
result (OAPR) were calculated.
Concordance and discordance values, derived from the logistic
regression analysis, were used to measure the association of
predicted probabilities and check the ability of the equation
to predict outcome. To evaluate the overall performance of the
equation, we considered several measures of predictive perform-
ance including discrimination (quantified by the area under the
ROC curve) and calibration (quantified by calibration slope)
[15–20].
To validate the equation, we randomly divide the data set into
two equal parts—a derivation (training) set and a validation
(confirmatory) set. The equation was developed and estimated
on the derivation set and tested and validated on the confirmatory
set using a cross-validation procedure. The average performance
was then calculated over two repetitions.
To compare the results obtained with the predictive equation
and the results obtained with various recommended and proposed
random capillary plasma glucose cut-points, we applied the
equation and those cut-points to the validation (confirmatory)
dataset. All statistical analyses were performed using SAS software




Table 1 describes the characteristics of the subjects divided
into derivation and validation sets. Figure 1(a) shows the
distribution of study population by reported post-prandial
















levels (and 25–75% intraquartile ranges) by post-prandial





 8 h). In general, RPG levels were highest 1–2 h post-





The predictive equation was calculated with the following













8.3390 + 0.0214 [age (years)] + 0.6764 [if female]




)] + 0.0934 [post-prandial time (hours)]





(mmol/ l)] + 0.0243 [random capillary plasma glucose (mmol/
l)]. Table 2 shows the maximum likelihood estimates for the
logistic regression function. The overall significance of the









with 7 degrees of freedom with 82% concordant pairs and
17.5% discordant pairs. The Hosmer-Lemeshow goodness of




 0.44) with 8 degrees of freedom. The EPV
was 159/7 = 23. Because no interactions, either alone or in
combination, added significantly to the equation, we did not
add any of these parameters. No potential outliers were
detected and the equation met the linearity assumption for
logistic regression analysis.
The probability level that provided an optimal cut-point











Age (years) 44 (15) 45 (14) 45 (15)
Mean (SD)
Sex (female) 298 (58) 294 (57) 296 (58)
n (%)
BMI (kg/m2) 29.7 (7.1) 29.8 (8.0) 29.8 (7.6)
Mean (SD)
Post-prandial time (0–8+ h) 3 (2) 3 (2) 3 (2)
Mean (SD)
Systolic blood pressure (mmHg) 130 (23) 129 (22) 130 (23)
Mean (SD)
HDL (mmol/ l) 1.2 (0.5) 1.2 (0.5) 1.2 (0.5)
Mean (SD)
Capillary plasma glucose (mmol/ l ) 5.9 (2.3) 6.2 (2.7) 6.1 (2.5)
Mean (SD)
NGT (2-h PG < 7.8 mmol/ l 
and/or FPG < 6.1 mmol/ l)
336 (65) 362 (70) 349 (68)
n (%)
IGT (2-h PG ≥ 7.8 mmol/ l) 144 (28) 118 (23) 131 (26)
n (%)
IFG (FPG ≥ 6.1 mmol/ l) 111 (22) 87 (17) 99 (20)
n (%)
DM (2-h PG ≥ 11.0 mmol/ l and/or 77 (15) 58 (11) 68 (13)
FPG ≥ 7.0 mmol/ l)
n (%)
DM, diabetes mellitus; IFG, impaired fasting glucose; IGT,  impaired glucose tolerance; NGT, 
normal glucose tolerance.
Table 1 Characteristics of the study 
populations
Figure 1 Distribution of study population by post-prandial time (a) and 
random plasma glucose (median and 25–75% IQR) by post-prandial time (b).
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logistic regression and ROC curve analysis, sensitivity was
55%, specificity 90% and PPV 65% (Fig. 2). The performance
of screening test depends on the cut-point used to define a pos-
itive test. We chose the cut-point of 0.38 to optimize specific-
ity. Choosing a probability level of 0.10 optimized sensitivity
(sensitivity 91%, specificity 39% and PPV 34%). Choosing a
probability of 0.22 produced equal sensitivity and specificity
(sensitivity 73%, specificity 73% PPV 49%).
Screening tests that discriminate well between dysglycaemic
and non-dysglycaemic individuals aggregate toward the upper
left corner of the ROC curve. The area under the curve quan-
tifies how well the screening test correctly distinguishes a dys-
glycaemic from a non-dysglycaemic person; the greater the
area under the curve, the better the performance of the screen-
ing test. A diagonal reference line (AUC = 0.50) defines points
where a test is no better than chance in identifying persons
with dysglycaemia. The area under the ROC curve was 0.82.
The calibration slope was 0.99.
When applied to the validation sample, the equation’s sens-
itivity was 53%, specificity 89% and PPV 63%. These repres-
ented relatively small decrements from the original equation.
When applied to the validation dataset with a 30% preval-
ence of dysglycaemia (the prevalence observed in the Egyptian
dataset), the predictive equation and a cut-point of 0.38
performed better than static random capillary plasma glucose
cut-points (Table 3). In general, the equation yielded higher
sensitivity, identified more new cases (true positives) and missed
fewer new cases (false negatives) than the static capillary
















 8.9 mmol/ l.
The equation yielded higher specificity and identified fewer





















 7.2 mmol/ l. The equation
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Behavioural and pharmacological interventions can delay or
prevent Type 2 diabetes in high risk populations [1–5,21]. In
addition, emerging evidence suggests that earlier diagnosis and
treatment of Type 2 diabetes may delay or prevent the develop-
ment of complications [22]. Based on the results of these
studies, it is likely that IFG and IGT will become targets for
clinical and public health intervention. Currently, the diagno-
sis of dysglycaemia requires 2-h 75-g oral glucose tolerance
tests. As has been amply documented, oral glucose tolerance
tests are not commonly performed in routine clinical practice
and alternative approaches to the diagnosis of dysglycaemia
must be developed [23–27]. For these reasons, it is desirable to
identify subpopulations at increased risk for dysglycaemia and
develop quick, non-invasive and inexpensive methods of iden-
tifying individuals with dysglycaemia.












Intercept −8.3390 ±0.739 — 0.0001 — —
Age (years) 0.0214 ±0.008 7.5 0.006 1.24* 1.06–1.44*
Sex (female) 0.6764 ±0.213 10.1 0.002 1.97 1.30–2.99
BMI (kg/m2) 0.0335 ±0.013 6.2 0.01 1.03† 1.01–1.06†
Post-prandial time (0–8 h) 0.0934 ±0.053 4.3 0.04 1.10† 1.01–1.21†
Systolic blood pressure (mm/hg) 0.0141 ±0.005 9.4 0.002 1.15* 1.05–1.26*
HDL (mmol/ l) −0.0110 ±0.005 4.7 0.03 0.998 0.997–0.999‡
Capillary plasma glucose (mmol/ l) 0.0243 ±0.003 73.5 0.0001 1.28* 1.21–1.35*
*Estimated ORs and 95% CIs for 10 unit increase.
†Estimated ORs and 95% CIs for 1 unit increase.
‡Estimated ORs and 95% CIs for 0.1 unit increase.
Figure 2 Receiver operator characteristic (ROC) curve. Points on the 
ROC curve represent the probability levels generated from the logistic 
regression analysis that was used to select the optimal cut-point. A 
probability value of 0.38 provided a sensitivity of 55% and a specificity 
of 90%. The area under the ROC curve was 0.82. Sensitivity and 
specificity of risk factors for the prediction of dysglycaemia were based 
on FPG ≥ 6.1 mmol/ l and/or 2-h PG ≥ 7.8 mmol/ l and were estimated 
















We have developed a multivariate predictive equation based
on age, sex, BMI, post-prandial time, systolic blood pressure,
HDL and capillary plasma glucose levels to access the likeli-
hood of dysglycaemia. The equation was 55% sensitive and
90% specific. In validation testing, the equation was 53% sen-
sitive and 89% specific. The relatively small decrement in sens-
itivity and specificity on validation testing suggest that the
equation has both internal validity and generalizability [28].
A number of recent studies have suggested that risk factor
questionnaires [29,30] and risk scores [25,31–36] can be used
to screen for dysglycaemia and undiagnosed diabetes. The area
under the ROC curves for the published risk scores have
ranged from 0.66 to 0.74 for dysglycaemia and from 0.74 to
0.87 for undiagnosed diabetes. The performance of our equa-
tion to screen for dysglycaemia, with an area under the ROC
curve of 0.82, exceeds that for published risk scores for dys-
glycaemia and is comparable with published risk scores for
undiagnosed diabetes. The sensitivity of the published risk
scores have ranged from 51 to 69% for dysglycaemia and from
72 to 81% for undiagnosed diabetes. The specificity has
ranged from 63 to 78% for dysglycaemia and 55 to 78% for
undiagnosed diabetes. Compared with these risk scores, at the
probability level of 0.38, our equation is less sensitive (55%)
but more specific (90%) than the risk scores for both dysgly-
caemia and undiagnosed diabetes.
The application of all screening tests requires a trade-off
between sensitivity and specificity. If a lower cut-point value is
used to define a positive test, sensitivity increases but specific-
ity decreases. This results in more complete ascertainment of
subjects with abnormal glucose tolerance, but substantially
more false positive subjects who require follow-up diagnostic
testing. The decision regarding acceptable levels of sensitivity
and specificity involves weighing the consequences of leaving
cases undetected (false negatives) and classifying healthy per-
sons as abnormal (false positives) [37,38]. Highly sensitive
tests are preferable if the failure to make an early diagnosis and
initiate treatment has dire health consequences. Highly specific
tests may be preferred if a disease is uncommon in the popula-
tion or if a false positive result can harm the subject emotion-
ally, physically or financially. In a substantial minority of
subjects, dysglycaemia may revert to normal on follow-up
testing [39–44]. In others, dysglycaemia may be slowly pro-
gressive but is not likely to be associated with short-term
complications. For these reasons, and because dysglycaemia is
an uncommon condition and follow-up diagnostic testing is
potentially harmful, we believe that specificity should be optim-
ized in screening. To avoid missing individuals with persistent
or progressive dysglycaemia, it is imperative that periodic re-
screening be performed.
Previously, using data from the same study, we developed an
empirical formula to screen for undiagnosed diabetes [9]. The
equation’s sensitivity was 65% and its specificity was 96%.
Compared with the former equation, our present equation for
dysglycaemia is less sensitive (55 vs. 65%) and less specific (90
vs. 96%). This indicates that the dysglycaemia equation does
not work as well as the equation to predict undiagnosed
diabetes. This may be due to the greater overlap of the distri-
butions of random glucose levels between the normal and
dysglycaemic populations (IFG, IGT and undiagnosed dia-
betes) compared with the population with undiagnosed diabetes.
Other possible explanations include the variability, poor
reproducibility and lack of test-to-test reliability of a 2-h PG of
7.8–11.0 mmol/ l for the prediction of IGT [39–44].
When we applied the equation for undiagnosed diabetes to
predict dysglycaemia, our dysglycaemia equation was more
sensitive (55 vs. 54%) and more specific (90 vs. 84%). This
suggests that for the same outcome (prediction of dysglycae-
mia), the dysglycaemia equation works better than the equa-
tion for undiagnosed diabetes. It is likely that the inclusion of
additional risk factors in the dysglycaemia equation (systolic
blood pressure and HDL cholesterol) account for the
improved performance.
Different ethnic groups may vary in their characteristics,
which may affect a predictive equation’s performance. It is
Table 3 Comparison of the performance of the predictive equation and capillary plasma glucose cut-points for a hypothetical population of 1000 with 














Equation 53 89 63 2.06 159 77 141
Capillary plasma glucose:
≥ 5.0 mmol/ l 94 21 25 0.51 282 553 18
≥ 5.6 mmol/ l 90 36 29 0.60 270 448 30
≥ 6.1 mmol/ l 73 67 39 0.95 219 231 81
≥ 6.7 mmol/ l 57 82 48 1.35 171 126 129
≥ 7.2 mmol/ l 46 88 55 1.64 138 84 162
≥ 7.8 mmol/ l 40 95 71 3.43 120 35 180
≥ 8.3 mmol/ l 37 97 83 5.29 111 21 189
≥ 8.9 mmol/ l 35 98 85 7.50 105 14 195
True positive = new cases = prevalence × sensitivity × n; false positive = 1-prevalence × 1-specificity × n; false negative = missed cases = prevalence 
× 1-sensitivity × n.
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important to assess the performance of the equation in differ-
ent ethnic groups [34,35,45,46]. Indeed, some have suggested
that ethnic group-specific cut-points may be needed for predict-
ive equations [35]. We applied our predictive equation for
undiagnosed diabetes [9], developed in the Egyptian popula-
tion, to data from 1065 predominantly Caucasian-American
subjects. The equation, which was 65% sensitive and 96%
specific in the Egyptian population, was 62% sensitive and
96% specific in the US population. Thus, it performed well in
another ethnic group. Although the variables included in the
equation are routinely available for most adult patients in
primary care in the United States, this may not be the case in
other settings. This may limit the generalizability of the
equation. Further evaluation of the dysglycaemia predictive
equation in different populations is needed to further establish
its generalizability.
In summary, by incorporating RPG data in combina-
tion with simple, available risk factor data, the predictive
equation performs better in the general population than any




90%, use of the equation with a cut-point of 0.38 misses
approximately 45% of persons with dysglycaemia. To
avoid missing these ‘false negative’ screenees, it is imperative
the repeat screening be performed periodically. The pre-
dictive equation has been designed to identify individuals at
increased risk for dysglycaemia who require further dia-
gnostic testing. The equation is designed to be used by primary
care practitioners in general clinical practice. It can also be
used by health systems with access to electronic medical
records. The multivariate equation can be implemented with
a number of inexpensive, programmable, hand-held calcu-
lators. We have programmed the formula and coefficients pres-
ented in the statistical methods section into a TI-83 graphic
and scientific calculator (Dallas, TX, USA). To obtain a prob-
ability value, the user enters the values for age (years), systolic
blood pressure (mmHg), HDL (mmol/ l), capillary plasma
glucose (mmol/ l), post-prandial time (0–8+ h), BMI (kg/m
 
2)
and sex (0 for male or 1 for female). The calculator prompts
the user by displaying the coefficient for the variable that
should be entered next. The result displayed is the calculated
probability that a subject has dysglycaemia (a number
between 0.0 and 1.0). The programming is available on
request. Using this device and a glucose meter, a health-care
professional can perform a quick point-of-care assessment of
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